{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T05:02:31Z","timestamp":1785560551280,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcjo.2025.02.014","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T23:01:36Z","timestamp":1742684496000},"page":"e689-e694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal clinical characteristics of patients with neurofibromatosis type 1"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8159-5769","authenticated-orcid":false,"given":"Lorenz","family":"Wassermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-7129","authenticated-orcid":false,"given":"Sandra","family":"Rezar-Dreindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-4015","authenticated-orcid":false,"given":"Gregor S.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Neumayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Stifter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2025.02.014_bib0001","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","article-title":"The diagnosis and management of neurofibromatosis type 1","volume":"103","author":"Ly","year":"2019","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2020.03.053","article-title":"Neurofibromatosis type 1-associated optic pathway glioma in children: a follow-up of 10 years or more","volume":"221","author":"Kinori","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0004","first-page":"264","article-title":"Neurofibromatosis: phenotype, natural history, and pathogenesis","volume":"67","author":"Wallace MR","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0006","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ajo.2003.09.055","article-title":"Optic radiation involvement in optic pathway gliomas in neurofibromatosis","volume":"137","author":"Liu","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/08820530701745223","article-title":"Neurofibromatosis type I: genetics and clinical manifestations","volume":"23","author":"Savar","year":"2008","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.icu.0000243016.90004.12","article-title":"Optic gliomas of the anterior visual pathway","volume":"17","author":"Liu","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0009","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2003.03.043","article-title":"Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy\u2014Results of the first French prospective study for the French Society of Pediatric Oncology","volume":"21","author":"Laithier","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajmg.a.20211","article-title":"Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome","volume":"122A","author":"King","year":"2003","journal-title":"Am J Med Genet A"},{"issue":"21 Suppl 1","key":"10.1016\/j.jcjo.2025.02.014_bib0011","article-title":"Functional outcome measures for NF1-associated optic pathway glioma clinical trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0012","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s00330-004-2433-y","article-title":"Pediatric brain MRI in neurofibromatosis type I","volume":"15","author":"Mentzel","year":"2005","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0013","first-page":"4095","article-title":"Optic pathway glioma and cerebral focal abnormal signal intensity in patients with neurofibromatosis type 1: characteristics, treatment choices and follow-up in 134 affected individuals and a brief review of the literature","volume":"36","author":"Friedrich","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/adc.87.1.65","article-title":"Neurofibromatosis type 1 and sporadic optic gliomas","volume":"87","author":"Singhal","year":"2002","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/a-0889-8256","article-title":"Guidelines for the diagnosis and management of paediatric and adolescent low-grade glioma (extrapolated from current SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low-Grade Glioma","volume":"231","author":"Gnekow","year":"2019","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0016","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1542\/peds.2007-3364","article-title":"Health supervision for children with neurofibromatosis","volume":"121","author":"Hersh","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0017","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejpn.2015.03.002","article-title":"Comparative study of the ophthalmological examinations in neurofibromatosis type 1. Proposal for a new screening algorithm","volume":"19","author":"Caen","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0018","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1542\/peds.2007-3364","article-title":"Health supervision for children with neurofibromatosis","volume":"121","author":"Hersh","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.908573","article-title":"Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1","volume":"9","author":"Zeid","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0020","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-023-10996-y","article-title":"Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas","volume":"23","author":"Armstrong","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-021-01032-y","article-title":"Neurofibromatosis in the era of precision medicine: development of MEK inhibitors and recent successes with selumetinib","volume":"23","author":"Galvin","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0022","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","article-title":"MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus","volume":"24","author":"De Blank","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0023","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","article-title":"Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience","volume":"147","author":"Esp\u00edrito Santo","year":"2020","journal-title":"J Neurooncol"},{"issue":"Suppl","key":"10.1016\/j.jcjo.2025.02.014_bib0024","article-title":"Visual development in infants: physiological and pathological mechanisms","volume":"22","author":"Br\u00e9mond-Gignac","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/WNO.0000000000001241","article-title":"Correlation between ophthalmologic and neuroradiologic findings in type 1 neurofibromatosis","volume":"42","author":"Godinho","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0026","doi-asserted-by":"crossref","first-page":"375","DOI":"10.17712\/nsj.2020.5.20200081","article-title":"Clinical spectrum of neurofibromatosis type 1 among children in a tertiary care center","volume":"25","author":"Bashiri","year":"2020","journal-title":"Neurosciences"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0027","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2017.02.027","article-title":"Predicting neurofibromatosis type 1 risk among children with isolated caf\u00e9-au-lait macules","volume":"76","author":"Ben-Shachar","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0028","first-page":"454","article-title":"An update on neurofibromatosis type 1: not just caf\u00e9-au-lait spots, freckling, and neurofibromas. An Update. Part I","volume":"107","author":"Hern\u00e1ndez-Mart\u00edn","year":"2016","journal-title":"Dermatol Clin Crit Diagn Dis"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148077","article-title":"Retinal oximetry with scanning laser ophthalmoscope in infants","volume":"11","author":"Vehmeijer","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3928\/01913913-20180925-02","article-title":"Prevalence of strabismus among children with neurofibromatosis type 1 disease with and without optic pathway glioma","volume":"56","author":"Dotan","year":"2019","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0031","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/112067210901900324","article-title":"The prevalence of anisometropia aniso-astigmatism and amblyopia in neurofibromatosis type 1","volume":"19","author":"Ardagil","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0032","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaapos.2015.06.003","article-title":"Strabismus in patients with neurofibromatosis type 1-associated optic pathway glioma","volume":"19","author":"Parness-Yossifon","year":"2015","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0033","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ophtha.2003.08.001","article-title":"A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children","volume":"110","author":"Holmes","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0034","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archopht.121.5.603","article-title":"A randomized trial of patching regimens for treatment of moderate amblyopia in children","volume":"121","author":"Repka","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0883073813520504","article-title":"Increased prevalence of ametropia in children with neurofibromatosis type 1 disease","volume":"30","author":"Dotan","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0036","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaapos.2014.01.010","article-title":"Anisometropia in children with neurofibromatosis type 1 and unilateral optic nerve glioma","volume":"18","author":"Dotan","year":"2014","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0037","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/bjo.2006.109082","article-title":"Refractive errors in neurofibromatosis type 1 and type 2","volume":"91","author":"Akinci","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0038","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ophtha.2003.06.008","article-title":"Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients","volume":"111","author":"Thiagalingam","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0039","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13023-022-02369-8","article-title":"An update on choroidal abnormalities and retinal microvascular changes in neurofibromatosis type 1","volume":"17","author":"Mallone","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2011.07.046","article-title":"Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1","volume":"119","author":"Viola","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0041","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13023-021-01773-w","article-title":"Hyperpigmented spots at fundus examination: a new ocular sign in neurofibromatosis type I","volume":"16","author":"Moramarco","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0042","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/bjo.86.3.282","article-title":"Corkscrew retinal vessels in neurofibromatosis type 1: report of 12 cases","volume":"86","author":"Muci-Mendoza","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0043","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2415-14-146","article-title":"Retinal microvascular abnormalities overlying choroidal nodules in neurofibromatosis type 1","volume":"14","author":"Abdolrahimzadeh","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0044","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/IAE.0000000000001578","article-title":"Retinal vascular abnormalities in a large cohort of patients affected by neurofibromatosis type 1: A study using optical coherence tomography angiography","volume":"38","author":"Parrozzani","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0045","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00417-005-1184-z","article-title":"Quantification and anatomic distribution of choroidal abnormalities in patients with type I neurofibromatosis","volume":"243","author":"Nakakura","year":"2005","journal-title":"Graefe's Arch Clin Exper Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0046","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.icu.0000158258.01681.40","article-title":"Review of optical coherence tomography for intraocular tumors","volume":"16","author":"Shields","year":"2005","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0047","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(00)02716-1","article-title":"Frequency of choroidal abnormalities in neurofibromatosis type 1","volume":"356","author":"Takaharu","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2025.02.014_bib0048","first-page":"851","article-title":"Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography","volume":"10","author":"Abdolrahimzadeh","year":"2016","journal-title":"Clin Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:21:50Z","timestamp":1759612910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418225001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0008418225001024"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.02.014","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal clinical characteristics of patients with neurofibromatosis type 1","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}